Markets
Why you need to take a closer look at your favorite stock index
Also in Weekend Reads: A positive case for the bond market, how prediction markets can pull you in, and a warning to those who benefit from GLP-1s.
Name
GLP-1s
2 stories in the last 7 days, reading neutral overall. The last day ran at 6.0× its usual pace.
- 7-day mood
- 0.0Neutral 0
- Stories, 7 days
- 2
- Last 24 hours
- 16.0× usual
- Sources
- 11in the latest 30
Mood and coverage · last 7 days
Market chart- GLP-1s · 6-hour average
- Hourly reading
- Stories per hour
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | 0.0 | 1 |
| Thu, Oct 8 | — | 1 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on GLP-1s
Newest firstGLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Healthcare
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Healthcare
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Healthcare
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Healthcare
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
Healthcare
Use of GLP-1s Like Ozempic Is Forcing Food Companies to Adapt
People on medications for weight loss are buying less food, shrinking their portion sizes and purchasing smaller clothes. Businesses are trying to adjust.
Finance
Bank of America spends more than $250 million on GLP-1s
Bank of America spends more than $250 million on GLP-1s
Healthcare
Lilly's revenue soars 48%, driven by demand for its GLP-1s
Lilly's sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Transport
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Shipping and logistics companies are tapping into the growing market of healthcare as cold chain and temperature-controlled facilities become more crucial.
Healthcare
GLP-1s are linked to a 17% drop in worker sick leave, new study finds
Here's how weight-loss drugs like Ozempic and Wegovy could reduce worker illness and save companies money.
I lost nearly 350 pounds without surgery or GLP-1s. It started with wall pushups and a trainer.
I lost nearly 350 pounds without surgery or GLP-1s. It started with wall pushups and a trainer.
Healthcare
Number of Americans taking GLP-1s for weight loss hits record high: Survey
A record number of Americans are taking GLP-1 drugs for weight loss, according to a new Gallup survey released Tuesday - a massive increase over the past two y…
Consumer
Just About Anyone Can Sell You GLP-1s Online Now
Welcome to the "Temu experience of telehealth," where everyone from Grindr to MAGA influencers can open a virtual clinic selling weight loss drugs and more.
A depressing new study found women had an easier time getting hired after losing weight on GLP-1s
A depressing new study found women had an easier time getting hired after losing weight on GLP-1s
I Was Scammed Buying GLP-1s Online. I'm Not Alone
Customers have complained that a telehealth network selling compounded GLP-1s has been ripping them off - even after it had to pay $5 million to clients as par…
Healthcare
A new wave of weight-loss therapies aims to be better than today's GLP-1s
Retatrutide is one of those drugs. It helped people lose a massive amount of weight in clinical trials. It also improved sleep apnea and knee pain.
Healthcare
Some people lose far more weight than others on GLP-1s like Wegovy. Here's why.
Emerging research shows there are 'super-responders' to GLP-1 drugs, and others who don't respond at all.
Healthcare
Weight loss and hair loss: The growing hair treatment market from GLP-1s
A common side effect of many GLP-1 drugs is hair loss. It's creating a formerly untapped but growing market for hair treatment products.
Commodities
Can GLP-1s curb alcohol use? A new study says the drugs can reduce heavy drinking.
A "gold standard" trial found that semaglutide helped reduce drinking in people with obesity who sought out treatment for alcohol-use disorder.
Consumer
Hershey says GLP-1s are driving higher gum and mint sales
Sales of Hershey's Ice Breakers rose 8% in the first quarter, thanks to the trend.
Healthcare
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
What a dietitian would eat in a day on GLP-1s to get enough protein, fiber, and nutrients
What a dietitian would eat in a day on GLP-1s to get enough protein, fiber, and nutrients
Consumer
As millions lose weight on GLP-1s, they're starting to turn to retailers to refresh their wardrobes
Apparel retailers could see an up to $13 billion annual boost in spending because of GLP-1 drugs, according to an estimate by equity research firm Bernstein.
Insomnia Cookies CEO: How GLP-1s Are Changing the Cookie Game
Insomnia Cookies CEO: How GLP-1s Are Changing the Cookie Game
It's time to rethink how we define obesity as millions turn to GLP-1s
BMI is just B.S. It doesn't accurately define what it means to be overweight.
Healthcare
How GLP-1s are changing the ways Americans buy medicine
Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.
Healthcare
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Consumer
McDonald's execs are figuring out how to handle more customers on GLP-1s
McDonald's execs are figuring out how to handle more customers on GLP-1s
Healthcare
GLP-1s represent the biggest problem with the US healthcare system
GLP-1s represent the biggest problem with the US healthcare system
